Skip to main content
SpringerLink
Log in

Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis

Effects of pancreatic enzymes and ranitidine

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Cyclosporin (CsA) is currently the main immunosuppressive agent used in organ transplantation with considerable improvement in graft survival. Oral CsA solution is highly lipophilic, and its bioavailability may be reduced in cystic fibrosis (CF) heart-lung transplant recipients with pancreatic, gastrointestinal, and hepatic insufficiency. The bioavailability of oral CsA solution in 7 CF transplant recipients (5 male and 2 female with a mean age of 27 years and a mean weight of 49 kg) and 3 non-CF heart-lung recipients (1 male and 2 female with a mean age of 41 years and a mean weight of 60 kg) was studied.

Following intravenous CsA administration, the kinetic curves were similar with no significant difference in the volume of distribution and clearance of CsA demonstrated between the CF and non-CF groups. The mean daily dose of oral CsA in 7 CF subjects (23.3 mg·kg−1) was significantly higher than the 3 non-CF heart-lung recipients (4.8 mg·kg−1). The mean maximum blood concentration of CsA for the oral dose was 776 ng·ml−1 for the 7 CF subjects, which was comparable with the mean peak values of 789 ng·ml−1 for the 3 non-CF control subjects. Poor enteral absorption of CsA probably accounts for the significantly lower mean bioavailability in the 7 CF subjects (14.9%) compared with the 3 non-CF control subjects (39.4%).

The effects on the bioavailability of oral CsA solution by pancreatic enzymes (Creon) and histamine-2 antagonist (ranitidine) were also evaluated in the 7 CF subjects. No significant difference was demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reitz BA, Bieber CP, Raney A, et al (1981) Orthotopic heart and combined heart and lung transplantation with cyclosporin-A immune suppression. Transplant Proc 13: 393–396

    Google Scholar 

  2. Kahan BD (1987) Immunosuppressive therapy with cyclosporin for cardiac transplantation. Circulation 75: 40–56

    Google Scholar 

  3. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al (1987) The effect of oral metoclopramide on the absorption of cyclosporin. Transplant Proc 19: 1730–1733

    Google Scholar 

  4. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Gray J, Van Thiel DH, Starzl TE (1985) Cyclosporin bioavailability in liver disease. Drug Intell Clin Pharmacol 19: 451

    Google Scholar 

  5. Tredger JM, Naoumov CM, Steward CM, et al (1988) Influence of biliary T tube clamping on cyclosporin pharmacokinetics in liver transplant recipients. Transplant Proc 20: 512–515

    Google Scholar 

  6. Grevel J (1988) Significance of cyclosporin pharmacokinetics. Transplant Proc 20: 428–434

    Google Scholar 

  7. Scott JP, Higenbottam TW, Hutter J, et al (1988) Heart-lung transplantation for cystic fibrosis. Lancet II: 192–194

    Google Scholar 

  8. Zentler-Munro PL, Northfield TC (1987) Pancreatic enzyme replacement — applied physiology and pharmacology (review). Aliment Pharmacol Ther 1: 575–591

    Google Scholar 

  9. Stead RJ, Skypala I, Hodson ME, et al (1987) Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis. Comparison with a standard enteric coated preparation. Thorax 42: 533–537

    Google Scholar 

  10. Yacoub MH, Banner NR, Khaghani A, et al (1990) Combined heart and lung transplantation for cystic fibrosis and subsequent Domino cardiac transplantation. J Heart Transplant 9: 459–467

    Google Scholar 

  11. Wong PY, Ma J (1990) Specific and nonspecific monoclonal 125I-Incstar assays. Transplant Proc 22: 1166–1170

    Google Scholar 

  12. Johnston A, Woollard RC (1983) STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods 9: 193–199

    Google Scholar 

  13. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al (1986) Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 11: 107–132

    Google Scholar 

  14. Cooney GF, Fiel SB, Shaw LM, Cavarocchi NC (1990) Cyclosporin bioavailability in heart-lung transplant candidates with cystic fibrosis. Transplantation 49: 821–823

    Google Scholar 

  15. Mancel-Grosso V, Bertault-Peres P, Barthelemy A, Chazalette JP, Durand A, Noirclerc M (1990) Pharmacokinetics of cyclosporine A in bilateral lung transplantation candidates with cystic fibrosis. Transplant Proc 22: 1706–1707

    Google Scholar 

  16. Tan KKC, Strickland SE, Trull AK, et al (1990) Altered pharmacokinetics of cyclosporin in heart-lung recipients with cystic fibrosis. Ther Drug Monit 12: 520–524

    Google Scholar 

  17. Venkataramanan R, Burckart GJ, Ptachcinski RJ, et al (1986) Cyclosporin pharmacokinetics in heart transplant patients. Transplant Proc 18: 768–770

    Google Scholar 

  18. Spino M, Chai RP, Isles AF, et al (1984) Cloxacillin absorption and disposition in cystic fibrosis. J Paediatr 105: 829–835

    Google Scholar 

  19. Finkelstein E, Halik J (1979) Aminoglycosides clearance in patients with cystic fibrosis. J Paediatrics 94: 163–164

    Google Scholar 

  20. Levy J, Smith AL, Koup JR et al (1984) Disposition of tobramycin in patients with cystic fibrosis. J Paediatr 105: 117–124

    Google Scholar 

  21. Isles A, Spiro M, Tabachnik E, et al (1983) Theophylline disposition in cystic fibrosis. Am Rev Respir Dis 127: 417–421

    Google Scholar 

  22. Weizman Z, Durie PR, Kopelman H, Vesely S, Forstner GG (1986) Bile acid secretion in cystic fibrosis — evidence for a defect unrelated to fat malabsorption. Gut 27: 1043–1048

    Google Scholar 

  23. Robb TA, Davidson GP, Kirubakaran C (1985) Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis. Gut 26: 1246–1256

    Google Scholar 

  24. Daring PB, Lepage G, Leroy C, Masson P, Roy CC (1985) Effect of taurine supplements on fat absorption in cystic fibrosis. Paediatr Res 19: 578–582

    Google Scholar 

  25. Quinton PM (1990) Cystic fibrosis: a disease in electrolyte transport. FASEB J 4: 2709–2717

    Google Scholar 

  26. Scott JP, Smyth RL, Higenbottam TW, McGoldrick JP, Wallwork J (1989) Cyclosporin dosing in cystic fibrosis after transplantation. Transplantation 48: 543–544

    Google Scholar 

  27. Cox KL, Isenberg JN, Ament ME (1982) Gastric acid hypersecretion in cystic fibrosis. J Paediatr Gastroenterol Nutr 1: 559–565

    Google Scholar 

  28. Kopelman H, Durie P, Gaskin K, Weizman Z, Forstner G (1985) Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med 312: 329–334

    Google Scholar 

  29. Burckart G, Starzl T, Williams L, et al (1985) Cyclosporin monitoring and pharmacokinetics in paediatric liver transplant patients. Transplant Proc 17: 1172–1175

    Google Scholar 

  30. Sokol RJ, Johnson KE, Karrer FM, et al (1991) Improvement of cyclosporin absorption in children after liver transplantation by means of water soluble vitamin E. Lancet 338: 212–214

    Google Scholar 

  31. Congden PJ, Bruce G, Rothburn MM, et al (1981) Vitamin status in treated patients with cystic fibrosis. Arch Dis Child 56: 708–714

    Google Scholar 

  32. Sokol RJ, Heubi JE, Butler-Simon N, McClung HJ, Lilly JR, Silverman A (1987) Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-alpha tocopheryl polyethylene glycol-1000 succinate. Gastroenterology 93: 975–985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiac Surgery, Royal Brompton, National Heart and Lung Hospital, London, UK

    V. T. Tsang & M. Yacoub

  2. Department of Cystic Fibrosis, Royal Brompton, National Heart and Lung Hospital, London, UK

    F. Heritier & M. E. Hodson

  3. Harefield Hospital, Harefield, Middlesex, UK

    N. Leaver

  4. Department of Clinical Pharmacology, St. Bartholomew's Hospital, London, UK

    A. Johnston

Authors
  1. V. T. Tsang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Heritier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Leaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. E. Hodson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Yacoub
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsang, V.T., Johnston, A., Heritier, F. et al. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Eur J Clin Pharmacol 46, 261–265 (1994). https://doi.org/10.1007/BF00192559

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00192559

Key words

Search

Navigation